Novel Therapeutic Strategies for Ovarian Cancer Stem Cells

Ovarian cancer (OC) is one of the most lethal gynecologic malignancies. Due to the lack of specific symptoms and screening methods, this disease is usually diagnosed only at an advanced and metastatic stage. The gold-standard treatment for OC patients consists of debulking surgery followed by taxane...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology Vol. 10; p. 319
Main Authors: Terraneo, Nastassja, Jacob, Francis, Dubrovska, Anna, Grünberg, Jürgen
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 17.03.2020
Subjects:
Auger electron and alpha particle emitters
cancer stem cells
epithelial-to-mesenchymal transition
L1CAM
Oncology
ovarian cancer
radioimmunotherapy
radioimmunotherapy
ovarian cancer
Auger electron and alpha particle emitters
cancer stem cells
L1CAM
epithelial-to-mesenchymal transition
therapeutic strategies
ISSN:2234-943X, 2234-943X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer (OC) is one of the most lethal gynecologic malignancies. Due to the lack of specific symptoms and screening methods, this disease is usually diagnosed only at an advanced and metastatic stage. The gold-standard treatment for OC patients consists of debulking surgery followed by taxane combined with platinum-based chemotherapy. Most patients show complete clinical remission after first-line therapy, but the majority of them ultimately relapse, developing radio- and chemoresistant tumors. It is now proposed that the cause of recurrence and reduced therapy efficacy is the presence of small populations of cancer stem cells (CSCs). These cells are usually resistant against conventional cancer therapies and for this reason, effective targeted therapies for the complete eradication of CSCs are urgently needed. In this review article, we highlight the mechanisms of CSC therapy resistance, epithelial-to-mesenchymal transition, stemness, and novel therapeutic strategies for ovarian CSCs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article was submitted to Radiation Oncology, a section of the journal Frontiers in Oncology
Reviewed by: Yoshihiko Hirohashi, Sapporo Medical University, Japan; Janneke Hoogstad-van Evert, Radboud University Nijmegen Medical Centre, Netherlands
Edited by: Paul N. Span, Radboud University Nijmegen Medical Centre, Netherlands
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2020.00319